Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1352458520942198 http://scihub22266oqcxt.onion/10.1177/1352458520942198 32662742!7493197!32662742     free     free     free       Mult+Scler 2020 ; 26 (10): 1256-1260 Nephropedia Template TP {{tp|p=32662742|t=2020. COVID-19 in multiple sclerosis: The Dutch experience |pdf=|usr=}}{{32662742}} gab.com Text COVID-19 in multiple sclerosis: The Dutch experience JO: Mult Scler http://www.kidney.de/pget.php?&tw=1&pmid=32662742 #FOAvip Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed. Twit Text FOAVip COVID-19 in multiple sclerosis: The Dutch experience ????Mult Scler http://www.kidney.de/pget.php?&tw=1&pmid=32662742 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32662742 #FOAvip English Wikipedia <ref>{{Cite pmid|32662742}}</ref> COVID-19 in multiple sclerosis: The Dutch experience #MMPMID32662742 Loonstra FC; Hoitsma E; van Kempen ZL; Killestein J; Mostert JP Mult Scler 2020[Sep]; 26 (10): 1256-1260 PMID32662742show ga Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed. |Adult[MESH] |Aged[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/blood/epidemiology/mortality/*physiopathology[MESH] |Female[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Immunologic Factors/*therapeutic use[MESH] |Intensive Care Units[MESH] |Lymphocyte Count[MESH] |Lymphopenia/*blood/epidemiology[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Sclerosis/*drug therapy/epidemiology[MESH] |Netherlands/epidemiology[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/epidemiology/mortality/*physiopathology[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]COVID-19 in multiple sclerosis: The Dutch experience (epmc).pdf DeepDyve Pubget Overpricing